Open AccessInflammatory and Cholesterol Risk in the FOURIER Trial
Author(s) -
Erin A. Bohula,
Robert P. Giugliano,
Lawrence A. Leiter,
Subodh Verma,
JeongGun Park,
Peter Sever,
Armando Lira Pineda,
Narimon Honarpour,
Huei Wang,
Sabina A. Murphy,
Anthony Keech,
Terje R. Pedersen,
Marc S. Sabatine
Publication year - 2018
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.118.034032
Subject(s) - evolocumab , medicine , pcsk9 , interquartile range , alirocumab , cardiology , stroke (engine) , population , unstable angina , clinical endpoint , myocardial infarction , rosuvastatin , c reactive protein , statin , placebo , gastroenterology , cholesterol , apolipoprotein b , lipoprotein , clinical trial , inflammation , apolipoprotein a1 , pathology , mechanical engineering , ldl receptor , alternative medicine , environmental health , engineering
In the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk), the PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor evolocumab reduced low-density lipoprotein cholesterol (LDL-C) and cardiovascular risk. It is not known whether the efficacy of evolocumab is modified by baseline inflammatory risk. We explored the efficacy of evolocumab stratified by baseline high-sensitivity C-reactive protein (hsCRP). We also assessed the importance of inflammatory and residual cholesterol risk across the range of on-treatment LDL-C concentrations.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom